HilleVax, Inc. (NASDAQ:HLVX) Given Average Rating of "Hold" by Brokerages

Shares of HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) have been given a consensus recommendation of "Hold" by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $3.00.

Separately, HC Wainwright restated a "neutral" rating and set a $2.00 price objective on shares of HilleVax in a report on Monday.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Intech Investment Management LLC bought a new position in HilleVax during the fourth quarter worth about $26,000. SG Americas Securities LLC increased its holdings in shares of HilleVax by 61.6% during the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock worth $38,000 after purchasing an additional 6,916 shares during the period. Ieq Capital LLC raised its position in shares of HilleVax by 71.1% in the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock valued at $47,000 after buying an additional 9,344 shares in the last quarter. Bank of Montreal Can raised its position in shares of HilleVax by 47.1% in the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock valued at $74,000 after buying an additional 11,459 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of HilleVax by 328.0% during the 4th quarter. Russell Investments Group Ltd. now owns 38,236 shares of the company's stock valued at $79,000 after acquiring an additional 29,303 shares during the period. 86.42% of the stock is owned by institutional investors.

HilleVax Stock Performance

HLVX traded down $0.01 during mid-day trading on Monday, reaching $1.44. The stock had a trading volume of 245,572 shares, compared to its average volume of 431,424. The firm's fifty day simple moving average is $1.78 and its two-hundred day simple moving average is $1.85. The stock has a market capitalization of $71.72 million, a P/E ratio of -0.46 and a beta of 0.76. HilleVax has a 52 week low of $1.37 and a 52 week high of $16.31.

HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.02). As a group, analysts expect that HilleVax will post -2.64 EPS for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.